Abstract: It is not clear how the blocking effect of angiotensin II receptors by olmesartan affects the functional recovery of pressure-overload hypertrophied heart. Hypertrophied heart was created by abdominal aortic banding above the celiac artery in Wistar rats at the age of eight weeks. Hypertrophied heart was excised and studied at 10 and 16 weeks after the operation (HT groups). For the last four weeks before the experiment, olmesartan (0.2 mg/kg per day) was administered subcutaneously by osmotic minipumps (Olm groups). Left ventricular function was measured by Langendorff perfusion. The levels of mRNA for angiotensin-converting enzyme (ACE), ACE2 and extracellular signal-regulated kinases (ERKs) in myocardium were analyzed by RT-PCR. Left ventricular systolic (þdP/dt max , left ventricular systolic pressure) and diastolic functions (ÀdP/dt max , tau) were impaired in HT groups, while in Olm groups they were significantly improved. The left ventricle to body weight (LV/BW) ratio increased significantly in HT groups, but in Olm groups the LV/BW ratio decreased significantly in comparison with HT groups. The ACE2 mRNA level was significantly higher in Olm groups as compared with HT groups. Plasma angiotensin II and the ERK mRNA level in HT groups increased significantly, but decreased in Olm groups in comparison with HT groups significantly. Olmesartan improved left ventricular function and hypertrophy through the increase of the ACE2 mRNA and decrease of both angiotensin II and ERK mRNA in pressure-overload rat heart.
Introduction
Myocardial hypertrophy and heart failure are important risk factors of cardiac surgery. The renin-angiotensin system (RAS) plays a key role in structural and functional remodeling in myocardial hypertrophy, and angiotensin (Ang) II is a major determinant in this process [De Mello and Jan Danser, 2000] . Ang II stimulates cardiac hypertrophy and fibrosis in ischemic heart failure models [Liu et al. 1998 ]. Cardiac hypertrophy is induced by mechanical load [Komuro et al. 1993 [Komuro et al. , 1990 Mann et al. 1989] and humoral factors such as angiotensin II (Ang II) [Baker et al. 1992] , endothelin-1 (ET-1) [Ito et al. 1991] and peptide growth factors [Parker and Schneider, 1991] . Ang II also activates a variety of protein kinases and signaling molecules such as protein kinase C (PKC), Raf-1 kinase (Raf-1), and extracellular signal-regulated protein kinases (ERKs) in cardiac hypertrophy [Zou et al. 1996] . Angiotensin-converting enzyme (ACE) catalyzes the formation of Ang II and thereby plays a key role in cardiorenal regulation and blood pressure control. In, 2000, a novel angiotensin-converting enzyme (ACE)-related carboxypeptidase, ACE2, was identified in the human heart Donoghue et al. 2000] and was characterized as an enzyme similar to ACE [Tipnis et al. 2000] . ACE 2 degrades Ang I into Ang-(1-9) and Ang II into Ang-(1-7) . Genetic inactivation of ACE 2 in mice resulted in severe cardiac dysfunction while cardiac and renal ACE 2 gene expression was reduced in three models of hypertension in which the ACE 2 gene mapped to quantitative trait loci previously detected by linkage analysis [Crackower et al. 2002] .
Olmesartan is a novel AT1 receptor blocker (ARB) synthesized by Daiichi Sankyo Co. Ltd (Tokyo, Japan). Gallagher and colleagues had reported first, that AT1 receptor blocker losartan and valsartan blocked the Ang II-mediated reduction in ACE 2 mRNA expression, and the reduction in ACE 2 protein by Ang II also was blocked by losartan in rat astrocytes [Gallagher et al. 2006] . However, the inhibitory effect of olmesartan on Ang-II mediated reduction in ACE 2 is not well understood. The purpose of this study was to investigate the effect of olmesartan on Ang II and ACE2 expression using rat myocardium from a pressure-overload left ventricular hypertrophied heart model. Furthermore, we investigated the cardioprotective effect of olmesartan on left ventricular function.
Methods
Hypertrophied rat heart model All animals received humane care in compliance with the Principles of Laboratory Animal Care formulated by the National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals prepared by the Institute of Laboratory Animal Resources. and published by the National Institutes of Health. Male Wistar rats (weight 160-190 g, aged eight weeks) were used to create the model of left ventricular hypertrophy (LVH). After anesthesia was induced with intraperitoneal (i.p.) pentobarbital sodium (30 mg/kg), a left laparotomy was performed, and then aortic banding at the diameter of 1 mm was carried out with a 3-0 silk suture at the level of the abdominal aorta above the celiac artery. Subsequent to the banding, the aortic coarctation gradually developed as the animal grew. Hypertrophied rats were divided into six groups. The heart was excised and studied at 10 and 16 weeks after the aortic banding operation (HT-10w group and HT-16w group, each n ¼ 8). During the final four weeks prior to the heart being excised, olmesartan (0.2 mg/kg per day) was infused subcutaneously by Alzet osmotic minipumps (2ML4, Durect Corporation, Cupertino, CA) (Olm-10w group and Olm-16w group, each n ¼ 8). These treatment groups were compared to control groups aged 10 and 16 weeks after the sham operation (C-10w group and C-16w group, each n ¼ 8).
Isolated heart preparation The rats were anesthetized by intraperitoneal pentobarbital sodium (30 mg/kg). Blood samples were collected from the inferior vena cava and 1000 U heparin was injected into the inferior vena cava. Hearts were rapidly excised and arrested in ice-cold modified Krebs-Henseleit buffered (KHB) solution. The modified KHB solution consisted of the following (in mM): NaCl 118, NaHCO 3 25, glucose 11.1, KCl 4.9, CaCl 2 2.7, MgSO 4 1.2, KH 2 PO 4 1.2, insulin 10 units/liter. And it was equilibrated with 95% O 2 À 5% CO 2 . The whole system was maintained at 37 C. Isolated hearts were perfused retrogradely via the ascending aorta at a constant pressure of 75-80 cm H 2 O. The heart was suspended in a sealed chamber from which the coronary effluent was collected. A latex balloon connected to a pressure transducer was inserted through the mitral valve into the left ventricle. Left ventricular pressure curves were recorded on a polygraph (RTA-1200M, Nihon Kohden Inc., Tokyo, Japan) connected to the pressure transducer. After 15 minutes of equilibration period, sequential measurements were made with left ventricular end-diastolic pressure (LVEDP) at 5, 10, 20, 30 and 40 mmHg. The maximal rate of contraction (+dP/dt max ) and left ventricular systolic pressure were used as measures of LV systolic function. The maximal rate of relaxation (-dP/dt max ) and isovolumic relaxation time (tau) were used as measures of LV diastolic function.
Radioimmunoassay of angiotensin I and angiotensin II Plasma concentrations of Ang I and Ang II were determined by radioimmunoassay from blood collected into chill tubes containing a mixture of 25 mmol/l ethylene-diamine-tetraacetic acid (Sigma Chemical Co., St. Louis, MO), 0.44 mmol/l 1,20-orthophenanthrolene monohydrate, 1 mmol/l Na þ parachloromercuribenzoate, and 3 mmol/l of WFML (rat renin inhibitor: acetylHis-Pro-Phe-Val-Statine-Leu-Phe). Radioimmunoassay was performed using rabbit anti-peptide serum (primary antibody) and a commercially available kit according to the manufacturer's instructions.
Extraction of RNA and reverse transcriptionpolymerase chain reaction Total RNA was isolated from rat hearts using an RNeasy total RNA isolation kit (Qiagen, Germany). Reverse transcription (RT) was performed with an RT kit (Promega, USA). One mg of total RNA was used as a template, and RTgenerated cDNAs encoding ACE and glyceraldehydes-3-phosphate dehydrogenase (GAPDH; internal control), ACE2 and ERK were amplified with polymerase chain reaction (PCR). The sequences of the primers for the amplification of cDNA were as follows:
The possible contamination of any PCR component was excluded by performing a PCR reaction with these components in the absence of RT product in each set of experiments (negative control). Twelve microliters of RT-PCR product was checked by using 2% agarose gel electrophoresis containing 0.2 mg/ml ethidium bromide, followed by photograph under ultraviolet transillumination. The levels of RNA expression were normalized to that of GAPDH mRNA in the same tissue sample. The appropriate number of PCR cycles and the optimal combination of the amount of the first-strand cDNAs were determined for each set of primers to ensure that all PCR reactions were carried out in the linear quantitative phase of the amplification process. The PCR products were fractionated on agarose gels, visualized by means of ethidium bromide staining and photographed. The photographs of ethidium bromide-stained gels were scanned with an imaging densitometer linked to a personal computer equipped with image analysis software. The size and optical density of the band produced by the PCR products were quantified by using the Kodak digital science one-dimensional image analysis software (EDAS 120, Eastman Kodak Company). For statistical comparison, samples in the experiment were tested to obtain the ratio of density of objective gene to GAPDH mRNA levels.
Statistical analysis
Statistical analysis for comparing data among each group was performed by parametric analysis followed by Welch's t-test using commercially available software (Statview, Abacus Concepts). All results were expressed as mean AE standard error (SE). A value of p50.05 was considered to be significant.
Results

Hypertrophied heart model
The left ventricle to body weight (LV/BW) ratio was used as an index of LV hypertrophy. The LV/ BW ratio was significantly higher in HT-10w group than that in C-10w group. Then, the ratio was significantly decreased in Olm-10w group. Similarly, the LV/BW ratio in HT-16w group was significantly higher than that in C-16w group, but it was significantly decreased in Olm-16w group. However, the LV/BW ratio in both Olm-10w and Olm-16w group was not improved at the control level (Table 1) .
Left ventricular function LV function was assessed in isolated perfused hearts. There was no significant difference in þdP/dt max and left ventricular systolic pressure among the C-10w, HT-10w and Olm-10w groups. In the HT-10w group, ÀdP/dt max was significantly decreased in comparison with that in the C-10w group. In the Olm-10w group, ÀdP/dt max was significantly improved in comparison with that in the HT-10w group, and there was no significant difference with that in the C-10w group (Table 2 ). In the HT-16w group, þdP/dt max , ÀdP/dt max and LV systolic pressure were significantly lower than that in the C-16w group, and in the Olm-16w group all the data were significantly improved more than that in HT-16w group, but þdP/dt max and ÀdP/dt max were still lower than that in C-16w group (Table 2) .
Plasma concentrations of Ang I and Ang II Plasma Ang I concentration was significantly increased in both HT groups (HT-10w group ¼ 2377.1 AE 129.3 pg/ml, HT-16w group ¼ 2589.4 AE 152.7 pg/ml) and Olm groups (Olm-10w group ¼ 2468.4 AE231.1 pg/ml, Olm-16w group ¼ 2273.5 AE 245.8 pg/ml) in comparison with control groups (C-10w group ¼ 669.1 AE 31.9 pg/ml, C-16w group ¼ 765.5 AE 31.2 pg/ml), but there was no significant difference between HT and Olm groups (Figure 1) . Plasma Ang II concentration was significantly increased in all HT groups (HT-10w group ¼ 479 AE 137.5 pg/ml, HT-16w group ¼ 492.6 AE 142.3 pg/ml) and Olm groups Figure 1 . Effect of olmesartan treatment for four weeks in hypertrophied rat heart on circulating levels of angiotensin I. C, control; HT, hypertrophied heart; Olm, hypertrophied heart treated with olmesartan. Values are expressed in mean AE SE. *p50.05 vs C-10w; #p50.05 vs C-16w. (Olm-10w group ¼ 352.2 AE 89.4 pg/ml, Olm-16w group ¼ 387.6 AE 135.2 pg/ml) in comparison with control groups (C-10w group ¼ 57.1 AE 8.5 pg/ml, C-16w group ¼ 64.6 AE 11.5 pg/ml), but significantly decreased in Olm groups in comparison with HT groups (Figure 2 ).
Expressions of mRNA for ACE and ACE2
The ACE mRNA level analyzed with RT-PCR showed a significant increase in both HT groups (HT-10w group ratio ¼ 2.710 AE 0.185, HT-16w group ratio ¼ 2.693 AE 0.159) and Olm groups (Olm-10w group ratio ¼ 2.242 AE 0.213, Olm-16w group ratio ¼ 2.319 AE 0.174) more than the control groups (C-10w group ratio ¼ 1.315 AE 0.092, C-16w group ratio ¼ 1.203 AE 0.110), while there was no significant difference between the HT and Olm groups (Figure 3 ).
The results of ACE2 mRNA expression showed a significant increase in both the Olm-10w group (ratio ¼ 1.917 AE 0.129) and the Olm-16w group (ratio ¼ 1.721 AE 0.084) in comparison with control groups (C-10w group ratio ¼ 1.255 AE 0.130, C-16w group ratio ¼ 1.013 AE 0.076) and HT groups (HT-10w group ratio ¼ 1.317 AE 0.122, HT-16w group ratio ¼ 1.114 AE 0.095). There was no significant difference between the control groups and the HT groups (Figure 4) .
Expression of mRNA for ERK
The expression of mRNA for ERK showed a significant increase in both the HT-10w group Figure 3. Effect of olmesartan treatment for four weeks in hypertrophied rat heart on ACE mRNA expression. C, control; HT, hypertrophied heart; Olm, hypertrophied heart treated with olmesartan. Values are mean AE SE. *p50.05 vs C-10w; yp50.05 vs C-16w. Figure 2 . Effect of olmesartan treatment for four weeks in hypertrophied rat heart on circulating levels of angiotensin II. C, control; HT, hypertrophied heart; Olm, hypertrophied heart treated with olmesartan. Values are mean AE SE. *p50.05 vs C-10w; #p50.05 vs HT-10w; yp50.05 vs C-16w; **p50.05 vs HT-16w.
(ratio ¼ 1.202 AE 0.098) and the HT-16w group (ratio ¼ 0.976 AE 0.072) in comparison with control groups (C-10w group ratio ¼ 0.467 AE 0.032 and C-16w group ratio ¼ 0.409 AE 0.021). Then, the expression of ERK mRNA was significantly decreased in both the Olm-10w group (ratio ¼ 0.735 AE 0.054) and the Olm-16w group (ratio ¼ 0.777 AE 0.061) compared with the HT10w group and the HT-16w group ( Figure 5 ).
Discussion
The important finding of this study was that the blockade of Ang II receptors (olmesartan) affected the increase of the ACE2 mRNA level, and decrease of both plasma angiotensin II concentration and ERK mRNA level, followed by improvement of left ventricular function with reducing left ventricular hypertrophy in pressure-overload rat heart. The LVH models used Figure 5. Effect of olmesartan treatment for four weeks in hypertrophied rat heart on ERK mRNA expression measured by RT-PCR. C, control; HT, hypertrophied heart; Olm, hypertrophied heart treated with olmesartan. Values are mean AE SE. *p50.05 vs C-10w; #p50.05 vs HT-10w; yp50.05 vs C-16w; **p50.05 vs HT-16w.
in this experiment were created by abdominal aortic banding as we had previously reported [Minakawa et al. 2003 ], and LV hypertrophy had been made chronic so that acute ischemic change or acute hormonal change would not have an influence on the process of hypertrophy. The degree of hypertrophy was assessed with LV/BW ratio, and turned out to be 25-40% increased in hypertrophied groups. It is known that in the transition to heart failure, diastolic dysfunction occurs first, and then systolic function becomes impaired, followed by decompensated heart failure [Yamakado and Nakano, 1990] . In the HT-10w group, diastolic function was significantly impaired more than in the C-10w group, as revealed in the results of ÀdP/ dt and tau, though systolic function stayed at the control level. Both systolic and diastolic function (þdP/dt, LVDP, ÀdP/dt and tau) was significantly deteriorated in the HT-16w group more than in the C-16w group. Therefore, the models used in the present study were considered to be a transition from an early stage of hypertrophied heart (HT-10w group) to the late stage of hypertrophied heart (HT-16w group) or early heart failure. In the Olm-10w group, diastolic function was significantly improved in comparison with the control level. Both systolic and diastolic function were significantly improved in the Olm-16w group more than in the HT-16w group, but still significantly lower than in the C-16w group. These results mean that olmesartan improves LV function in the earlier and later stage of LV hypertrophy.
ACE2 is a carboxypeptidase that is insensitive to known ACE inhibitors [Crackower et al. 2002; Donoghue et al. 2000] and exhibits a high catalytic efficiency for the generation of Ang-(1-7) from Ang II since only dynorphin A and apelin 13 were hydrolyzed by ACE 2 with kinetics comparable to those of Ang II to Ang-(1-7) hydrolysis [Vickers et al. 2002] . Ablation of ACE 2 in mice causes severe cardiac dysfunction, suggesting that there is an important function of ACE 2 as a regulator of heart function [Crackower et al. 2002] . A recent study reported that ACE2 was unchanged during the process of ventricular remodeling in postmyocardial infarction but olmesartan increased ACE2 mRNA [Ishiyama et al. 2004] . In our study, we also found a significant increase in the ACE2 mRNA expression level in Olm groups. Administration of olmesartan caused partial reversal of cardiac hypertrophy and left ventricular dysfunction. This was associated with the increase of cardiac ACE 2 mRNA without changing ACE mRNA expression levels. It is reported in neonatal rat cardiomyocytes that aldosterone decreases ACE2 mRNA expression and increases ACE mRNA levels [Yamamuro et al. 2008] . We suppose that olmesartan may reduce the decrease in ACE2 mRNA level through the inhibition of aldosterone production. On the other hand, Gallagher and colleagues reported that Ang II reduced ACE2 mRNA expression in rat astrocytes [Gallagher et al. 2006] . The mechanism by which olmesartan increases the expression level of ACE2 is still unclear and further studies will be needed to clarify this mechanism.
Because of a lack of negative feedback on renin, it is thought that administration of ARBs increases Ang II levels. Several studies have reported that ARBs increased renin activity and Ang II levels [Fogari et al. 2002; Pool et al. 1999] . However Ichikawa and Takayama [2001] reported that long-term treatment of hypertensive patients with olmesartan resulted in reduction of the plasma Ang II level. Also, Agata et al. [2006] reported the plasma Ang II level was not significantly increased by olmesartan in stroke-prone spontaneously hypertensive rats (SHRSP), while Ang II increased significantly by co-administration of olmesartan and Ang-(1-7) antagonist, because Ang-(1-7) inhibits ACE activity [Tom et al. 2001] . In agreement with their results, we found that the plasma Ang II level was significantly decreased and ACE2 mRNA level significantly increased in Olm groups more than in HT groups. In the classic pathway of the RAS, Ang I is converted by ACE to Ang II, and converted by ACE2 to Ang (1-9). The function of Ang (1-9) is not well understood. ACE2 directly converts Ang II to Ang-(1-7), and ACE2 also acts as an ACE inhibitor [Danilczyk and Penninger, 2006] . Ang-(1-7) plays an important role in the RAS by reducing blood pressure and anti-remodeling effect through AT2 receptor stimulation [Agata et al. 2006] . Additional effects of the inhibition of ACE by Ang-(1-7) were the inhibition of kininase II and enhancement of the effect of bradykinin [Agata et al. 2006] . Chronic infusion of Ang-(1-7) reduced heart Ang II levels and increased cardiac ACE2 expression levels in rats [Mendes et al. 2005; Widdop et al. 1999] . Furthermore, Igase et al. [2008 Igase et al. [ , 2005 reported that olmesartan increased ACE2 and Ang-(1-7) expression in aorta or carotid artery of spontaneously hypertensive rats. As Agata et al. [2006] have reported, the findings in our study showed that olmesartan inhibited ACE activity through increased expression of ACE2 and Ang-(1-7) in the manner of an ACE inhibitor to reduce the plasma Ang II level in pressure-overload hypertrophied rat heart.
Ang II plays an important role in mechanical stress-induced cardiac hypertrophy, and there are also other effects to induce hypertrophic responses. Mechanical stress directly activates the protein kinase cascade of phosphorylation including PKC and MAP kinases, and the activated PKC induces the secretion of Ang II. The secreted Ang II amplifies the signals directly evoked by mechanical stress [Yamazaki et al. 1995] . The Ang II-evoked signal transduction pathway leads to the activation of ERKs, which are reportedly critical for the development of cardiac hypertrophy. It is reported that Ang II activates the Raf-1/ERK cascade mainly through PKC-dependent pathways, while tyrosine kinases, including the Src family tyrosine kinases or Ras, may have little effect on Ang II-induced activation of Raf-1 and ERKs [Zou et al. 1996] . In this study, the plasma Ang II levels and expressions of ERK mRNA were both decreased in Olm groups more than in HT groups. These findings suggest that olmesartan may contribute to reduction of cardiac hypertrophy by decreasing plasma Ang II levels.
There are limitations of this study. First, we have not examined whether the antihypertrophic effect was canceled by co-administration of ACE2 inhibitor or Ang-(1-7) antagonist, but it has been reported that angiotensin II level and anti-remodeling effect were canceled with the increase of expression level of ACE2 by co-administration of Ang-(1-7) antagonist in the study using the hypertensive rat model [Agata et al. 2006] . Second, it was not clear whether the inhibitory effect upon ACE2 by olmesartan was a particular effect or similar to the effect of other ARBs. Further study will be needed in the future to examine the role of other ARBs in this process. Third, we studied ACE2 only at the mRNA level, but post-transcriptional level of ACE2 will need to be analyzed in the future.
We conclude that blockade of AT1 receptors (olmesartan) increased the ACE2 mRNA level, and both angiotensin II and ERK mRNA level were decreased in parallel in pressure-overload rat heart. Olmesartan improved left ventricular function with reducing left ventricular hypertrophy, especially in the early stage of hypertrophy in left ventricular pressure-overload rat heart. Further study needs to be performed to elucidate the causal association between the increase in ACE2 levels and the decrease in Ang II and ERK levels as well as the improvement in left ventricular function when ACE2 antagonists become commercially available.
